AbbVie Inc. is 106.5x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($399.47 B vs $3.75 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | KNSA | ABBV |
|---|---|---|
| Market cap | $3.75 B | $399.47 B |
| US-listed rank | #1625 | #28 |
| Revenue (latest FY) | $677.56M | $61.16B |
| Net income (latest FY) | $59.01M | $4.23B |
| Net margin | 8.7% | 6.9% |
| P/E (trailing FY) | 63.6 | 94.5 |
| SEC filings | 733 | 1,008 |
AbbVie Inc. is 106.5x more valuable than Kiniksa Pharmaceuticals, Ltd. by market capitalization ($399.47 B vs $3.75 B).
In their latest fiscal years, Kiniksa Pharmaceuticals, Ltd. reported $677.56M in revenue while AbbVie Inc. reported $61.16B.
Full pages: Kiniksa Pharmaceuticals, Ltd. and AbbVie Inc., or browse the full rankings.